This Career Development Program (CDP) will be used to prepare new Moffitt investigators at the rank of Assistant Member (Assistant Professor) or equivalent, particularly those already in the field of cutaneous malignancy research, or established Moffitt investigators at the rank of Associate Member (Associate Professor) or higher who are new to the field for careers in translational research of cutaneous malignancies. It will also ease their transition to independence as investigators either in the laboratory or as clinical trialists. The Moffitt Skin SPORE career development program will provide guidance, advice, mentoring, evaluation, and financial resources for continuing support for up to two faculty-level persons per year for 2-3 years each. All prospective projects have a mentor listed that is affiliated with the Skin SPORE or the Comprehensive Melanoma Research Center (CMRC) at Moffitt. The goal is to allow appropriate and motivated individuals to develop an independent research career in translational science focused on cutaneous malignancies. It is not meant as a training program for graduate students, postdoctoral fellows, or clinical fellows in hematology-oncology, surgical oncology or dermatology. In collaboration with the Moffitt Lung SPORE, one CDP award per year may be co-supported by the Skin SPORE, promoting cross-SPORE fertilization. Dr. James Mule will lead the CDP. He has extensive experience in mentoring, research and administration, including serving as a faculty mentor/preceptor on numerous K08, K12, K99/R00 and ACS Fellowship awards, as well as the PI of two T32 training grants. Applications will be reviewed by an Award Evaluation Committee chaired by Dr. Mule using a scientific standard similar to a NIH study section. Scores of 1 (exceptional) to 9 (poor) will be assigned for categories of Significance, Innovation, Scientific quality. Collaboration, and Potential for publication and external funding; with brief justifications and overall impression), using a review form that we had employed previously for use in the CMRC. Progress reports will be required from all funded CDP project applicants at the end of the first six months, and again at the end of the first year of funding. The progress reports will be reviewed by the Award Evaluation Committee consisting of the Moffitt Skin SPORE IAC (see above for a list of members) and ad hoc members. Published manuscripts, abstracts accepted and the potential for translational impact will constitute the most important criteria for renewal of funding for an additional year.

Public Health Relevance

The Pre-SPORE grant at Moffitt expanded by the resources of the CMRC has previously chosen five investigators whose current cutaneous malignancy-related peer reviewed funding totals $1.2 million. Three of those faculty members are now among the funded investigators with proposals submitted as full Projects or to the DRP of the Moffitt Skin SPORE, which speaks to the potential significance and translational impact of the current CDP.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
H. Lee Moffitt Cancer Center & Research Institute
United States
Zip Code
Prieto-Granada, Carlos; Castner, Nicholas; Chen, Ann et al. (2018) Behavior of Cutaneous Adnexal Malignancies: a Single Institution Experience. Pathol Oncol Res :
Abate-Daga, Daniel; Ramello, Maria C; Smalley, Inna et al. (2018) The biology and therapeutic management of melanoma brain metastases. Biochem Pharmacol 153:35-45
Konno, Hiroyasu; Yamauchi, Shota; Berglund, Anders et al. (2018) Suppression of STING signaling through epigenetic silencing and missense mutation impedes DNA damage mediated cytokine production. Oncogene 37:2037-2051
Eroglu, Zeynep; Ozgun, Alpaslan (2018) Updates and challenges on treatment with BRAF/MEK-inhibitors in melanoma. Expert Opin Orphan Drugs 6:545-551
Zhu, Genyuan; Brayer, Jason; Padron, Eric et al. (2018) OMIP-049: Analysis of Human Myelopoiesis and Myeloid Neoplasms. Cytometry A 93:982-986
Zhu, Genyuan; Nemoto, Satoshi; Mailloux, Adam W et al. (2018) Induction of Tertiary Lymphoid Structures With Antitumor Function by a Lymph Node-Derived Stromal Cell Line. Front Immunol 9:1609
Ramello, Maria C; Haura, Eric B; Abate-Daga, Daniel (2018) CAR-T cells and combination therapies: What's next in the immunotherapy revolution? Pharmacol Res 129:194-203
Eroglu, Zeynep; Zaretsky, Jesse M; Hu-Lieskovan, Siwen et al. (2018) High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553:347-350
Phadke, Manali; Remsing Rix, Lily L; Smalley, Inna et al. (2018) Dabrafenib inhibits the growth of BRAF-WT cancers through CDK16 and NEK9 inhibition. Mol Oncol 12:74-88
Saglam, Ozlen; Naqvi, Syeda M H; Zhang, Yonghong et al. (2018) Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience. Melanoma Res 28:586-591

Showing the most recent 10 out of 62 publications